A biotechnology company about to enter clinical stage with two of its three leading-edge cancer drugs
in cancer therapeutics
Learn more
Improving patient lives and increasing survival rates
Our vision is to achieve a significant increase in the survival rate of patients with specific cancers through ground-breaking scientific discovery and personalized medicine using our proprietary molecules.Innovation-driven development
One of AC BioScience’s innovative approaches is characterized by the way we develop and apply new vascular normalizers that help drugs to better access solid tumors and oxygenation, thereby increasing the efficacy of all types of chemo- and radiotherapy.
Clinical trial Phase 2/3 in 2022.
Learn more
Reverting the tumor phenotype
With a Beta-carboline derivative showing outstanding pre-clinical results, our aim is to revert the tumor phenotype in order to improve MHC-1 mediated antigens presentation, and thereby potentiate the efficacy of anti PD-1 therapy.
Clinical trial Phase 1 in 2023.
Learn more
Exploring biotherapy
We are also currently validating a patented cationic amphipathic peptide (CAP6). This molecule is at the forefront of a shift towards cancer “biotherapy”, and has shown exceptional promise in in vivo tests for the treatment of lung cancer (NSCLC).Learn more